Ahmad Mazin M. Safar

Researcher

UAMS

Also affiliated: Central Arkansas Veterans Healthcare System (2024); Arkansas Department of Agriculture (2022)

Unknown Researcher

5 pubs

Research Areas

Biomedical Subjects

Links

Research Group

OverviewAI-generated summary

Ahmad Mazin M. Safar's research focuses on identifying vulnerabilities in cancer, particularly pancreatic cancer, through the study of molecular interactions. His work investigates the Kras-p53 mutational interface as a target for synthetic lethality (SL) approaches in cancer therapy. Safar has explored the transcriptional readout of wild-type p53 as a method for screening synthetic lethality in cancer, as well as interrogating the Kras-p53 transcriptional readout for SL applications. Additionally, his research extends to examining the duration of immune checkpoint inhibitors (ICI) in oncology, suggesting that longer treatment durations may not always be beneficial. Safar also investigates nodal metastasis as a potential immune indicator in cancer therapy and explores therapeutic overactivation strategies. He has a significant number of shared publications with collaborators at the University of Arkansas for Medical Sciences, including Farah Mazahreh, Liyan Mazahreh, and Samuel L. Schach.

Metrics

Publications: 5

Selected Publications

Abstract 1124: Mining the Kras-p53 mutational interface for synthetic lethality (SL) in pancreatic adenocarcinoma (PA) (2025)

Cancer Research DOI OpenAlex
Abstract 3214: The duration of immune checkpoint inhibitors (ICI) in oncology: Longer is not better (2025)

Cancer Research DOI OpenAlex
Abstract 5582: Interrogating the K-ras/p53 transcriptional readout for synthetic lethality applications (2025)

Cancer Research DOI OpenAlex
A Case Report on Pulmonary Tumor Embolism in a Patient With a Metastatic Gastrointestinal Stromal Tumor Invading the Inferior Vena Cava: Tumor or Thrombus? (2025)

Cureus DOI OpenAlex
Ongoing Radiographic Response for Over 20 Months in Metastatic Cancer Without Continued Immune Checkpoint Inhibitor (ICI) Dosing (2025)

Cureus DOI OpenAlex
Tumor Response to Immune-Oncology Therapy Despite High-Dose Steroid Intervention in a Patient With Papillary Renal Cell Carcinoma and Immune-Related Myasthenia Gravis (2025)

Cureus 2 citations DOI OpenAlex
Case of Immune Checkpoint Inhibitor Induced Myasthenia Gravis (2024)

Cureus DOI OpenAlex
Abstract 3856: Nodal metastasis as an immune indicator in cancer (ca) therapy (2024)

Cancer Research DOI OpenAlex
Abstract 1177: The chronology of immune-related adverse events (irAEs)-mechanistic implications (2024)

Cancer Research DOI OpenAlex
Abstract 1567: Honing in on the metastasis machinery (2024)

Cancer Research DOI OpenAlex
Weight loss (WL) as a predictive factor for immune oncology (IO). (2023)

Journal of Clinical Oncology DOI OpenAlex
Emergence of Chronic Lymphocytic Leukemia During Admission for COVID-19: Cause or Coincidence? (2022)

Cureus 5 citations DOI OpenAlex
Reduced Plasma Short-Chain Fatty Acid (SCFA) Concentrations Are Not Associated With Markers of Muscle Health in Non-Small Cell Lung Cancer (2021)

Current Developments in Nutrition DOI OpenAlex
Therapeutic Implications of Angiogenesis in Cancer (2017)

2 citations DOI OpenAlex
Integrating Collaborative Learning and Competition in a Hematology/Oncology Training Program (2016)

Journal of Cancer Education 2 citations DOI OpenAlex